Cellular @entity1618 is more effective than viral XXXX in decreasing venous thrombosis.

@entity32 @entity24780 @entity1750 @entity535 @entity19 @entity1618 @entity715
BACKGROUND: Systemic administration of cellular interleukin-10 (cIL-10) and gene transfection of viral interleukin-10 (vIL-10) at @entity715 induction @entity32 . Only cIL-10, despite sharing an 84% @entity535 sequence homology with vIL-10, decreases @entity715 through mechanisms yet to be determined. METHODS: C57BL/6 @entity19 ( @entity19 , n99) were studied. Inferior vena caval @entity715 was created by inferior vena caval ligation and the animals were sacrificed and evaluated at days 2 and 6 after ligation. At @entity715 induction groups received intravenous 0.25 microg of cIL-10, 0.25 microg of vIL-10, or saline (untreated controls). Evaluations included @entity715 mass and vein wall leukocyte counts, protein levels, and reverse-transcription polymerase chain reaction mRNA levels of P- and @entity24780 , @entity1750 , and @entity1618 . Groups were compared by analysis of variance and t tests. RESULTS: Less @entity715 was noted at both days 2 and 6 in animals treated with cIL-10. At day 2 only, vein wall leukocyte counts revealed a significant decrease in neutrophils in cIL-10 animals versus controls, with no significant differences for vIL-10 animals. In cIL-10-treated animals, P-selectin protein levels were decreased at day 6, along with a decreased @entity715 mass, without significant differences in @entity24780 , @entity1750 , or @entity1618 protein levels. vIL-10 treated animals showed increased @entity24780 mRNA and @entity715 mass versus controls on day 6. CONCLUSIONS: cIL-10 is more antithrombotic/anti-inflammatory than vIL-10. This may be the result of cIL-10 decreasing P-selectin protein expression and vIL-10 increasing @entity24780 mRNA levels.
